Mereo Biopharma Investor Relations Material
Latest events
Study Update
Mereo Biopharma
Q1 2025
13 May, 2025
Q4 2024
26 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Mereo Biopharma Group
Access all reports
Mereo Biopharma Group plc is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare diseases and oncology. The company has a diverse portfolio of product candidates in various stages of clinical development, including treatments for conditions such as osteogenesis imperfecta, Alpha-1 anti-trypsin deficiency, and different types of cancer. Among its leading candidates are etigilimab, an antibody designed for tumor treatment, and alvelestat, intended for Alpha-1 anti-trypsin deficiency. Founded in 2015, Mereo Biopharma Group plc is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
MREO
Country
🇺🇸 United States